Altimmune

Altimmune

Yahoo Finance • 16 days ago

Leerink Sees Altimmune (ALT) As An Attractive Play In The MASH Therapeutics Market

Altimmune, Inc. (NASDAQ:ALT), backed by significant analyst-implied upside, ranks among the overlooked penny stocks to buy right now. Fresh analyst confidence in the company's MASH drug candidate follows strong data that continues to build... Full story

Yahoo Finance • last month

Altimmune shifts headquarters to New Jersey, targeting biopharma talent and cost savings

[Usa, New-York City. Jersey City from Manhattan] Philippe TURPIN/Photononstop via Getty Images * Altimmune (ALT [https://seekingalpha.com/symbol/ALT]) said that [https://seekingalpha.com/filing/309723326] it will relocate its headquarte... Full story

Yahoo Finance • last month

Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight

New York, USA, June 08, 2026 (GLOBE NEWSWIRE) -- Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM... Full story

Yahoo Finance • 2 months ago

GLP-1 Sales Forecast Jumps To $150 Billion By 2030

This article first appeared on GuruFocus. TD Cowen has lifted its global GLP-1 sales forecast to $150 billion by 2030, up from its prior $139 billion estimate issued just over a year ago, signaling that demand for the drug class populariz... Full story

Yahoo Finance • 3 months ago

Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

GAITHERSBURG, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its first qu... Full story

Yahoo Finance • 3 months ago

Here is Why Altimmune Inc. (ALT) Appears to be an Attractive Penny Stock

Altimmune Inc. (NASDAQ:ALT) is one of the 10 most shorted penny stocks to buy. On March 19, Truist began coverage of Altimmune Inc. (NASDAQ:ALT) with a $12 price target, leading to a whopping 315% upside potential at the prevailing level.... Full story

Yahoo Finance • 3 months ago

Altimmune Shareholders Approve All AGM Proposals, Boost Authorized Shares to 400M

Altimmune logo Key Points All AGM proposals approved: Shareholders elected the company's nine director nominees to one-year terms and approved every item presented at the virtual annual meeting. Capital structure increased: Stockholders... Full story

Yahoo Finance • 5 months ago

Altimmune to start late-stage trial for MASH candidate this year

[Close up image of wooden cubes with alphabet Q4 on office desk.] mohd izzuan With its Q4 2025 financials on Thursday, Altimmune (ALT [https://seekingalpha.com/symbol/ALT]) announced plans to begin a late-stage trial this year to test its... Full story

Yahoo Finance • 6 months ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3 (Reuters) - Shares of obesity drugmakers and developers slid on Tuesday after Novo ​Nordisk forecast a sharper-than-expected sales decline ‌for 2026, underscoring intensifying competition in the blockbuster weight-loss market. Eli ‌... Full story

Yahoo Finance • 6 months ago

Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. One of the best biotech stocks on our list is Altimmune, Inc. TheFly reported on January 27 that Barclays initiated coverage of ALT with an Overweight rating... Full story

Yahoo Finance • 7 months ago

Altimmune posts mid-stage trial data showing antifibrotic activity of lead asset in MASH

[Human Internal Digestive Organ Liver Anatomy] magicmine/iStock via Getty Images Altimmune (ALT [https://seekingalpha.com/symbol/ALT]) on Friday announced initial results from a mid-stage trial for its lead asset pemvidutide in metabolic... Full story

Yahoo Finance • 7 months ago

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint Additional weight loss from 24 to 48 weeks with 1.8 mg dose, without plateauing Favorabl... Full story

Yahoo Finance • 8 months ago

Altimmune CEO Vipin Garg To Step Down; Stock Down In Pre-Market

(RTTNews) - Altimmune, Inc.(ALT), a developer of novel peptide-based therapeutics for liver and metabolic diseases, said on Monday that its Chief Executive Officer, Vipin Garg, will step down with effect from January 1, 2026. Subsequently... Full story

Yahoo Finance • 8 months ago

Altimmune Announces CEO Transition and Succession Plan

Jerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer Transition follows seven years of strong leadership by Dr. Garg GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Na... Full story

Yahoo Finance • 8 months ago

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that... Full story

Yahoo Finance • 8 months ago

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis improvement Pemvidutide demonstrated significant reductions in liver fibrosis and improvements in non-in... Full story

Yahoo Finance • 8 months ago

Altimmune to Participate in Two Upcoming Investor Conferences

GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that... Full story

Yahoo Finance • 9 months ago

Metsera the US obesity biotech at centre of Novo, Pfizer bidding war

By Bhanvi Satija LONDON (Reuters) -Metsera has become the obesity drug market's hottest ticket. The New York-based biotech is at the centre of a bidding war between Novo Nordisk and Pfizer, both vying for access to its pipeline of experi... Full story

Yahoo Finance • 9 months ago

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that... Full story

Yahoo Finance • 9 months ago

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

Oral presentation to highlight 24-week efficacy and safety data Poster to feature results of AI-based analyses of liver fibrosis reduction GAITHERSBURG, Md., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clini... Full story